Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
CADTH
Record ID 32015000156
English
Authors' recommendations:
One low quality RCT, one low quality retrospective cohort study and two case reports suggest that nabilone may be effective in preventing nausea and vomiting following surgery, treating intractable vomiting associated with HIV/AIDS, and treating weight loss in patients with hepatitis C virus undergoing treatment with interferon-ribavirin. However, given the limitations of these studies, it is difficult to draw strong conclusions about the effectiveness of nabilone in these conditions. No evidence-based guidelines addressing the use of nabilone in the treatment of weight loss due to medical conditions or for the treatment of non-chemotherapy associated nausea and vomiting were identified.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/sep-2014/RC0585%20Nabilone%20Update%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Nausea
- Vomiting
- Dronabinol
- Weight Loss
- Treatment Outcome
- Drug-Related Side Effects and Adverse Reactions
- Safety
- Canada
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.